COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …

Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

Background In immunocompromised patients, persistent SARS-CoV-2 viral shedding and
relapsing COVID-19 pneumonia have been described. Currently, little is known about the …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of
COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter …

SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that
patients with comorbidities are at higher risk of a severe disease course. The role of …

Background Little is known about targeted (antiviral or monoclonal antibody) anti-SARS-
CoV-2 treatment in immunocompromised patients with COVID-19. Objectives To assess the …

Although several innovative and repurposed drugs have been approved for the treatment of
COVID-19 during the last year, we still do not have evidence-based knowledge on the best …

Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …

Background Antiviral and antibody therapies for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are being recommended for high-risk patients, but the potential …